Cot Modulator Compounds for Improved Solubility and Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to modulate the expression or activity of Cot protein, which is involved in inflammatory diseases and cancer, leading to unaddressed conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, diabetes, sepsis, psoriasis, and graft rejection.
Innovation Solution
Development of compounds that modulate the expression or activity of Cot protein, including pharmaceutical compositions and methods for their use in treating diseases mediated by Cot, with specific structures defined by Formula I and its derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of inflammatory diseases and cancer is attempted, but effective agents to modulate Cot protein expression or activity are lacking
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (Formula I and Formula II) that modulate Cot protein activity. The chemical parameters of the compounds are optimized to achieve effective inhibition of Cot, thereby treating diseases mediated by Cot protein without affecting other pathways excessively.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to modulate Cot protein activity. These compounds act as mediators between the therapeutic goal and the biological target (Cot protein), enabling indirect control of inflammatory pathways and cancer progression through Cot inhibition.
2Reliability
If new compounds are developed to modulate Cot, then therapeutic benefits are achieved, but solubility and systemic exposure must be improved
Solution Approach 1:
The patent optimizes physical-chemical parameters of the compounds including solubility characteristics. The molecular structures are designed and modified to improve aqueous solubility while maintaining Cot inhibitory activity, enabling better systemic exposure and pharmacokinetic properties for therapeutic application.
Data Source
AI summary
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.